Compare EOS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOS | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2004 | 2018 |
| Metric | EOS | MGTX |
|---|---|---|
| Price | $21.54 | $9.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 141.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.98 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $19.44 | $6.62 |
| 52 Week High | $24.03 | $15.35 |
| Indicator | EOS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 28.24 |
| Support Level | $21.17 | $8.84 |
| Resistance Level | $21.71 | $10.71 |
| Average True Range (ATR) | 0.22 | 0.48 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 75.55 | 2.99 |
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.